Affimed N.V. (NASDAQ:AFMD) reports 1Q17 loss; Revenues Plummet

Affimed N.V. (NASDAQ:AFMD) reports 1Q17 earnings loss; Revenues Plummet

0
179

Affimed N.V. (NASDAQ:AFMD) a clinical-stage biopharmaceutical company, reported net loss for the first quarter of € 7.76 million or  € 0.19 per share, compared to loss  € 8.46 million or € 0.25 per share for the year-ago quarter.

The Revenue for first quarter decreased 79% to € 0.40 million from € 1.94 million in the same quarter last year.

Dr. Adi Hoess, CEO, said: We are continuously advancing our NK-cell engager pipeline in hematological and solid tumors, developing several well-differentiated programs, Furthermore, clinical data from a subset of patients in our GHSG-sponsored Phase 2a trial with AFM13 are very encouraging, as they provide further evidence of efficacy as monotherapy in heavily pre-treated patients.